

(fee 10/96)

PTO/SB/16/(6-95)
Approved for use through 04/11/98. OMB 0651-0037
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

PROVISIONAL APPLICATION COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION under 37 CFR 1.53 (b)(2).

18351 U.S. PTO
09/15/03

19587 U.S. PTO
60/503137
09/15/03

Docket Number		D-3111P		Type a plus sign (+) inside this box -	+
INVENTOR(S)/APPLICANT(S)					
LAST NAME	FIRST NAME	MIDDLE INITIAL	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)		
Acheampong Tang-Liu Chang Power	Andrew Diane James David	N. F.	Irvine, CA Newport Beach, CA Newport Beach, CA Trabuco Canyon, CA		
TITLE OF THE INVENTION (280 characters max)					
METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS					
CORRESPONDENCE ADDRESS					
FRANK J. UXA 4 VENTURE, SUITE IRVINE, CA 92618					
STATE	CA	ZIP CODE	92618	COUNTRY	USA
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/>	Specification	Number of Pages	33	Small Entity Statement	
<input type="checkbox"/>	Drawing(s)	Number of Sheets		Other(specify)	
METHOD OF PAYMENT (check one)					
<input type="checkbox"/>	A check or money order is enclosed to cover the Provisional filing fee			PROVISIONAL FILING FEE AMOUNT (\$)	\$160.00
<input checked="" type="checkbox"/>	The Commissioner is hereby authorized to charge filing fees and credit deposit Account Number:		01-0885		

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.


- No.
- Yes, the name of the U.S. Government agency and the Government contract number are: _____

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith

Martin A. Voet, Reg. No. 25,208, Robert Baran, Reg. No. 25,806, Carlos A. Fisher, Reg. No. 36,510, Stephen Donovan, Reg. No. 33,433, and Frank J. Uxa, Reg. No. 25,612, Donald E. Stout, Reg. No. 34,493; Robert D. Buyan, Reg. No. 32,460; Kenton R. Mullins, Reg. No. 36,331; Jo Anne M. Ybaben, Reg. No. 42,243, Linda Allyson Fox, Reg. No. 38,883, Kyle D. Yesland, Reg. No. 45,526, Greg S. Holtrigel, Reg. No. 45,374, Louse S. Heim, Reg. No. 32,337.

Respectfully submitted,

SIGNATURE



FRANK J. UXA, REG. NO. 25,612

Date

SEPTEMBER 15, 2003

- Additional inventors are being named on separately numbered sheets attached hereto

PROVISIONAL APPLICATION FILING ONLY

SEND TO: Commissioner of Patents, PO Box 1450, Alexandria, VA 22313-1450

DOCKET NO.: D-3111P

THE ENCLOSED PROVISIONAL PATENT APPLICATION OF ACHEAMPONG
ET AL IS BEING FILED IN ACCORDANCE WITH SECTION 37 CFR
1.10 BY EXPRESS MAIL AND SHOULD BE ACCORDED A FILING DATE

September 15, 2003

SEE THE EXPRESS MAIL CERTIFICATE ATTACHED TO THE APPLICATION.

D-3111P

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT

In re application of:
ACHEAMPONG ET AL.) Group Art Unit: N/A
)
Serial No. N/A) Examiner: N/A
)
Dated: Submitted herewith)
)
For: METHODS OF PROVIDING THERAPEUTIC)
EFFECTS USING CYCLOSPORIN)
COMPONENTS) ATTN: MS PROVISIONAL
PATENT APPLICATION

Express Mail Mailing Label No. EV 059889887US

Date of Deposit: SEPTEMBER 15, 2003

I hereby certify that the following documents as identified below are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and are addressed to the Commissioner for Patents, MS Provisional Patent Application, PO Box 1450, Alexandria, VA 22313-1450.

1. Provisional Application Cover Sheet;
2. Application Data Sheet
3. Application
4. Return receipt postcard.

The 4 above-identified documents are enclosed herewith.

Respectfully submitted,



Janet E. McGhee, Office of
Frank J. Uxa
Attorney for Applicant
Reg. No. 36,331
4 Venture, Suite 300
Irvine, CA 92618
(949) 450-1750
Facsimile (949) 450-1764

METHODS OF PROVIDING THERAPEUTIC EFFECTS
USING CYCLOSPORIN COMPONENTS

5 The present invention relates to methods of providing
desired therapeutic effects to humans or animals using
compositions including cyclosporin components. More
particularly, the invention relates to methods including
administering to an eye of a human or animal a
therapeutically effective amount of a cyclosporin component
10 to provide a desired therapeutic effect, preferably a
desired ophthalmic or ocular therapeutic effect.

The use of cyclosporin-A and cyclosporin A derivatives
to treat ophthalmic conditions has been the subject of
various patents, for example Ding et al U.S. Patent
15 5,474,979; Garst U.S. Patent 6,254,860; and Garst U.S.
6,350,442, this disclosure of each of which is incorporated
in its entirety herein by reference. In addition,
cyclosporin A compositions used in treating ophthalmic
conditions is the subject of a number of publications.
20 Such publications include, for example, "Blood
concentrations of cyclosporin a during long-term treatment
with cyclosporin a ophthalmic emulsions in patients with
moderate to severe dry eye disease," Small et al, *J Ocul
Pharmacol Ther*, 2002 Oct, 18(5):411-8; "Distribution of
25 cyclosporin A in ocular tissues after topical
administration to albino rabbits and beagle dogs,"
Acheampong et al, *Curr Eye Res*, 1999 Feb, 18(2):91-103b;
"Cyclosporine distribution into the conjunctiva, cornea,
lacrimal gland, and systemic blood following topical dosing
30 of cyclosporine to rabbit, dog, and human eyes," Acheampong
et al, *Adv Exp Med Biol*, 1998, 438:1001-4; "Preclinical
safety studies of cyclosporine ophthalmic emulsion,"

Angelov et al, *Adv Exp Med Biol*, 1998, 438:991-5;
"Cyclosporin & Emulsion & Eye," Stevenson et al,
Ophthalmology, 2000 May, 107(5):967-74; and "Two
5 multicenter, randomized studies of the efficacy and safety
of cyclosporine ophthalmic emulsion in moderate to severe
dry eye disease. CsA Phase 3 Study Group," Sall et al,
Ophthalmology, 2000 Apr, 107(4):631-9. Each of these
publications is incorporated in its entirety herein by
reference. In addition, cyclosporin A-containing oil-in-
10 water emulsions have been clinically tested, under
conditions of confidentiality, since the mid 1990's in
order to obtain U.S. Food and Drug Administration (FDA)
regulatory approval.

Examples of useful cyclosporin A-containing emulsions
15 are set out in Ding et al U.S. Patent 5,474,979. Example
1 of this patent shows a series of emulsions in which the
ratio of cyclosporin A to castor oil in each of these
compositions was 0.08 or greater, except for Composition B,
which included 0.2% by weight cyclosporin A and 5% by
20 weight castor oil. The Ding et al patent placed no
significance in Composition B relative to Compositions A,
C and D of Example 1.

Over time, it has become apparent that cyclosporin A
emulsions for ophthalmic use preferably have less than 0.2%
25 by weight of cyclosporin A. With cyclosporin A
concentrations less than 0.2%, the amount of castor oil
employed has been reduced since one of the functions of the
castor oil is to solubilize the cyclosporin A. Thus, if
reduced amounts of cyclosporin are employed, reduced
30 amounts of castor oil are needed to provide effective
solubilization of cyclosporin A.

There continues to be a need for providing enhanced

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.